

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 October 2024 (10.10.2024)



(10) International Publication Number
WO 2024/209339 A1

(51) International Patent Classification:
C07D 498/22 (2006.01) *A61P 35/00* (2006.01)
A61K 31/553 (2006.01)

(21) International Application Number:
PCT/IB2024/053182

(22) International Filing Date:
02 April 2024 (02.04.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/494,346 05 April 2023 (05.04.2023) US
63/507,621 12 June 2023 (12.06.2023) US
63/540,044 22 September 2023 (22.09.2023) US
63/598,907 14 November 2023 (14.11.2023) US
63/550,564 06 February 2024 (06.02.2024) US
63/568,399 21 March 2024 (21.03.2024) US

(71) Applicant: **PFIZER INC.**, [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: **BURKE, Benjamin Joseph**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **BURTEA, Alexander**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **DEFOREST, Jacob Cole**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **NAGATA, Asako**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **PLANKEN, Simon Paul**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **SPANGLER, Jillian Elyse**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **SUTTON, Scott Channing**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **WISNIEWSKA, Hanna Maria**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **YANG, Shouliang**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 66 Hudson Boulevard East, 11th Floor, New York, New York 10001-2192 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: PYRIDO[4,3-*D*]PYRIMIDINE COMPOUNDS

(57) Abstract: The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders and conditions such as cancers.

WO 2024/209339 A1